Literature DB >> 28059920

Local Excision Techniques for Rectal Cancer After Neoadjuvant Chemoradiotherapy: What Are We Doing?

Fraser McLean Smith1, Abdul Ahad, Rodrigo Oliva Perez, John Marks, Krzysztof Bujko, Richard J Heald.   

Abstract

BACKGROUND: Recent evidence shows that the majority of rectal cancers demonstrate occult tumor scatter after neoadjuvant chemoradiotherapy that can extend for several centimeters under adjacent normal-appearing mucosa beside the residual mucosal abnormality or scar.
OBJECTIVE: This systematic review aimed to determine all of the published selection criteria and technical descriptions for local excision to date with regard to this phenomenon. DATA SOURCES: PubMed, MEDLINE, and Embase were searched using the following key words: rectal cancer, local excision, radiotherapy, and neoadjuvant. STUDY SELECTION: Studies that assessed local excision of rectal cancer after neoadjuvant chemoradiotherapy were included. Duplicate series were excluded from final analysis. INTERVENTION: All of the data points were tabulated and analyzed using Microsoft Excel. MAIN OUTCOME MEASURES: Criteria for patient selection, surgical technique, clinical restaging, pathologic assessment, and indications for completion surgery were analyzed.
RESULTS: After exclusions, data from 25 studies that in total evaluated local excision in 1001 patients were included. Compared with the single accepted technique of total mesorectal excision, described techniques for local excision after neoadjuvant therapy demonstrate significant variability in many critical technical issues, such as marking/tattooing original tumor margins before neoadjuvant therapy, using pretreatment tumor size/stage as exclusion criteria, and specifically stating lateral excision margins. Where detailed, the majority of local recurrences occurred in patients with clear pathological margins, yet significant variation existed for pathological assessment and reporting, with few studies detailing R status and some not reporting margin status at all. Significant variability also existed for adverse tumor features that mandated completion surgery, and, importantly, many series describe patients refusing completion surgery where indicated. LIMITATIONS: We were unable to perform meta-analysis because studies lacked sufficient methodologic homogeneity to synthesize.
CONCLUSIONS: The observations from this study prompt additional study, standardization of technique, and cautious use of local excision of rectal cancer in the setting of neoadjuvant chemoradiotherapy.

Entities:  

Mesh:

Year:  2017        PMID: 28059920     DOI: 10.1097/DCR.0000000000000749

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  8 in total

1.  SSAT State-of-the-Art Conference: Advances in the Management of Rectal Cancer.

Authors:  Evie Carchman; Daniel I Chu; Gregory D Kennedy; Melanie Morris; Marc Dakermandji; John R T Monson; Laura Melina Fernandez; Rodrigo Oliva Perez; Alessandro Fichera; Marco E Allaix; David Liska
Journal:  J Gastrointest Surg       Date:  2018-09-13       Impact factor: 3.452

2.  Comparative analysis of modified Bacon operation and double stapler operation in the treatment of rectal cancer.

Authors:  Jianyong Yang; Lijun Tian; Liyun Niu; Chunbao Zhai
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

Review 3.  Transanal Local Excision of Rectal Cancer after Neoadjuvant Chemoradiation: Is There a Place for It or Should Be Avoided at All Costs?

Authors:  Rodrigo Oliva Perez; Guilherme Pagin São Julião; Bruna Borba Vailati
Journal:  Clin Colon Rectal Surg       Date:  2022-02-28

Review 4.  Multidisciplinary management of elderly patients with rectal cancer: recommendations from the SICG (Italian Society of Geriatric Surgery), SIFIPAC (Italian Society of Surgical Pathophysiology), SICE (Italian Society of Endoscopic Surgery and new technologies), and the WSES (World Society of Emergency Surgery) International Consensus Project.

Authors:  Mauro Podda; Patricia Sylla; Gianluca Baiocchi; Michel Adamina; Vanni Agnoletti; Ferdinando Agresta; Luca Ansaloni; Alberto Arezzo; Nicola Avenia; Walter Biffl; Antonio Biondi; Simona Bui; Fabio C Campanile; Paolo Carcoforo; Claudia Commisso; Antonio Crucitti; Nicola De'Angelis; Gian Luigi De'Angelis; Massimo De Filippo; Belinda De Simone; Salomone Di Saverio; Giorgio Ercolani; Gustavo P Fraga; Francesco Gabrielli; Federica Gaiani; Mario Guerrieri; Angelo Guttadauro; Yoram Kluger; Ari K Leppaniemi; Andrea Loffredo; Tiziana Meschi; Ernest E Moore; Monica Ortenzi; Francesco Pata; Dario Parini; Adolfo Pisanu; Gilberto Poggioli; Andrea Polistena; Alessandro Puzziello; Fabio Rondelli; Massimo Sartelli; Neil Smart; Michael E Sugrue; Patricia Tejedor; Marco Vacante; Federico Coccolini; Justin Davies; Fausto Catena
Journal:  World J Emerg Surg       Date:  2021-07-02       Impact factor: 5.469

5.  Additional 4-week capecitabine during the resting periods after 6-week neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: long-term oncologic outcomes.

Authors:  Sang Woo Park; Jin Soo Kim; Ji Yeon Kim; Kyung Ha Lee
Journal:  Ann Surg Treat Res       Date:  2018-05-29       Impact factor: 1.859

6.  The Clinical Significance of Mesenteric Lymphocytes in Human Colorectal Cancer.

Authors:  Zi-Xin Wu; Fei Wang; Liang Li; Yuan Yao; Jie Long; Qing-Qing Luo; Zhi-Bin Zhao; Wang-Lin Li; Jie Cao; Zhe-Xiong Lian
Journal:  Front Oncol       Date:  2021-09-16       Impact factor: 6.244

Review 7.  Towards personalized treatment of T2N0 rectal cancer: A systematic review of long-term oncological outcomes of neoadjuvant therapy followed by local excision.

Authors:  Roberto Peltrini; Nicola Imperatore; Maria Michela Di Nuzzo; Gianluca Pellino
Journal:  J Gastroenterol Hepatol       Date:  2022-06-03       Impact factor: 4.369

Review 8.  International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancer.

Authors:  Emmanouil Fokas; Ane Appelt; Alexandra Gilbert; David Sebag-Montefiore; Claus Rödel; Robert Glynne-Jones; Geerard Beets; Rodrigo Perez; Julio Garcia-Aguilar; Eric Rullier; J Joshua Smith; Corrie Marijnen; Femke P Peters; Maxine van der Valk; Regina Beets-Tan; Arthur S Myint; Jean-Pierre Gerard; Simon P Bach; Michael Ghadimi; Ralf D Hofheinz; Krzysztof Bujko; Cihan Gani; Karin Haustermans; Bruce D Minsky; Ethan Ludmir; Nicholas P West; Maria A Gambacorta; Vincenzo Valentini; Marc Buyse; Andrew G Renehan
Journal:  Nat Rev Clin Oncol       Date:  2021-08-04       Impact factor: 66.675

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.